Monday - April 13, 2026

ENDRA Life Sciences (NASDAQ: NDRA) Targets Billions With TAEUS® Liver Imaging Technology

As the global race to treat metabolic dysfunction–associated steatotic liver disease (MASLD) and expand GLP-1 therapies accelerates, a critical challenge is emerging across the pharmaceutical industry: clinical trial infrastructure is struggling to scale—especially liver imaging. With trial sizes increasing, durations … Continue reading